Navigation Links
Omeros Announces Publication of Data From Antifibrinolytic Program
Date:2/10/2011

rol of blood loss during surgery or resulting from trauma. Omeros' agents are designed to selectively inhibit plasmin, the enzyme responsible for fibrinolysis and dissolving blood clots, while avoiding significant inhibition of kallikrein and Factor XIa, important enzymes in the coagulation cascade. These agents could provide a superior replacement for the antifibrinolytic agents Trasylol® (aprotinin), tranexamic acid and epsilon aminocaproic acid.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release and include the ability of Omeros' antifibrinolytic agents to provide more effective bleeding control with fewer side effe
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Licenses Novel Antifibrinolytic Agents
2. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
3. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
4. Omeros to Present at the BioCentury NewsMakers Conference
5. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
6. Omeros Successfully Unlocks Orphan GPCRs
7. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
8. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
9. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
10. Daniel K. Spiegelman Elected to Board of Directors of Omeros
11. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... July 13, 2014 ... Tokio veranstalteten F&E-Tagung meldete ... zur Neuausrichtung seines Forschungsrahmenprogramms. Die Tagung bot ... die fortgeschrittenen klinischen Programme und die Konzernstrategie ... Tagung bestand darin, aktuelle Meldungen zu den ...
(Date:7/13/2014)... 2014  Eli Lilly and Company (NYSE: ... non-clinical study in genetically engineered mice examining combination ... antibody N3pG and beta-secretase inhibitor BACE (LY2811376). Data ... in removing clumps of amyloid-beta protein in the ... lead to Alzheimer,s disease (AD) – than use ...
(Date:7/11/2014)... 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced ... for use in portable vaporizers, which contains CBD, ... in cannabis, cannabidiol offers consumers a THC-free product ... other vaporizer technology. Photo - ... 483 different compounds which are currently known, two ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... strategic transaction processSAN DIEGO, May 7 ADVENTRX ... today announced results from its bioequivalence study of ... have comparable overall safety as Taxotere(R), the reference ... severe toxicities. However, pharmacokinetic equivalence, the primary ...
... is to Enhance Patient Safety and Reduce Health Care ... will join in a pilot program, contributing data on ... the data collected, it will be possible to identify ... patient safety while reducing overall costs to the health ...
Cached Medicine Technology:ADVENTRX Announces Results From ANX-514 Bioequivalence Study 2ADVENTRX Announces Results From ANX-514 Bioequivalence Study 3ADVENTRX Announces Results From ANX-514 Bioequivalence Study 4ADVENTRX Announces Results From ANX-514 Bioequivalence Study 5National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 2National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 3
(Date:7/13/2014)... MillionaireCasket.com is a professional supplier of funeral ... caskets are selling well in the global market. Recently, the ... and launched a special offer for all the newly ... the company’s cherry caskets are made with superb materials. As ... people to show respect to the departed saint. MillionaireCasket.com is ...
(Date:7/13/2014)... get the best treatment and variations in the quality ... for blood cancer patients still varies widely between regions ... survival in European adults to date, published in ... that 5-year survival for most cancers of the blood ... reflecting the approval of new targeted drugs in the ...
(Date:7/13/2014)... Carolinas Healthcare System celebrated today the ... HealthCare System - Anson located in Anson County. The ... Hospital in Wadesboro. , Located on U.S. Highway 74, ... previous facility. Situated on a 10-acre site, the new ... room drop-off, helipad, healing garden, and 15 beds. With ...
(Date:7/13/2014)... research in Nature Genetics identifies a ... that causes eosinophillic esophagitis (EoE), opening up potential ... food allergy. , EoE is a chronic ... triggered by allergic hypersensitivity to certain foods and ... cells called eosinophils (part of the body,s immune ...
(Date:7/13/2014)... July 13, 2014 Chromatography system ... components from various types of biological samples such ... the sample mixture into two phase, namely mobile ... mobile phase run over the stationary phase, followed ... components that provide the separation of mixture. Chromatography ...
Breaking Medicine News(10 mins):Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3
... direct marketing promotional products company, offers a specialty store filled ... ... Lewiston, ME (PRWEB) February 19, 2009 -- Crestline ... that trades on its easy, customer-friendly ordering process, offers ...
... Natrecor for a Use Not Approved By the Food ... has intervened in two whistleblower suits filed in the ... Inc. and its parent company, Johnson & Johnson Inc., ... for a use not approved by the Food and ...
... Indicates a 40% Reduction of Intraocular Pressure at Two ... today that it has surpassed 1000 implantation procedures with ... reduces intraocular pressure (IOP) for the treatment of glaucoma. ... President and Founder of SOLX, "as it validates the ...
... to Consumer-Directed Health Plans Continues, Watson Wyatt/National Business Group ... expect health care cost increases to hold steady at ... plans (CDHPs) in 2010 in an effort to control ... Wyatt, a leading global consulting firm, and the National ...
... to risk-taking, too, study finds, , , THURSDAY, Feb. ... makes people love skydiving, mountain-climbing or other intense ... the brain that has been linked to addictive ... researchers studied volunteers who were grouped as either ...
... percent less likely than men to receive a critical ... stroke, according to a Michigan State University study. , ... Diego at the International Stroke Conference, organized by the ... plasminogen activator, or tPA, first approved as a treatment ...
Cached Medicine News:Health News:Crestline is the Source for Great Green Giveaways 2Health News:Crestline is the Source for Great Green Giveaways 3Health News:United States Joins Suits Against Scios and Johnson & Johnson 2Health News:United States Joins Suits Against Scios and Johnson & Johnson 3Health News:SOLX Announces 1000th Gold Shunt Implantation Milestone for Glaucoma Treatment 2Health News:Health Care Benefit Cost Increases to Remain at 6 Percent in 2009 2Health News:Health Care Benefit Cost Increases to Remain at 6 Percent in 2009 3Health News:Thrill-Seekers' Brains May Be Wired Differently 2Health News:Women less likely to receive critical care after a stroke, MSU researchers find 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: